Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERO CERo Therapeutics	$9.55 -10.6%	$12.05	$6.71 ▼ $895.40	$3.73M	0.41	309,161 shs	247,102 shs
ENVB Enveric Biosciences	$1.24 -2.4%	$1.27	$1.01 ▼ $11.55	$3.06M	0.53	778,318 shs	467,769 shs
GPLB Green Planet Bioengineering	$0.04	$0.11	$0.02 ▼ $0.70	$800K	3.07	3,055 shs	N/A
SXTP 60 Degrees Pharmaceuticals	$2.30 -5.7%	$2.47	$1.41 ▼ $35.99	$3.38M	2.89	579,256 shs	11,952 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERO CERo Therapeutics	0.00%	-10.58%	+7.98%	-34.59%	-98.40%
ENVB Enveric Biosciences	0.00%	-2.36%	+5.97%	-10.79%	-86.80%
GPLB Green Planet Bioengineering	0.00%	0.00%	-63.64%	-92.16%	+7,900.00%
SXTP 60 Degrees Pharmaceuticals	0.00%	+11.11%	-11.20%	+25.00%	+81.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CERO CERo Therapeutics	3.7391 of 5 stars	3.7	4.0	0.0	0.0	2.4	0.8	0.0
ENVB Enveric Biosciences	2.9935 of 5 stars	3.5	4.0	0.0	0.0	2.7	0.0	1.3
GPLB Green Planet Bioengineering	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	2.6372 of 5 stars	3.3	3.0	0.0	0.0	2.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERO CERo Therapeutics	3.33	Buy	$45.00	371.20% Upside
ENVB Enveric Biosciences	3.00	Buy	$10.00	706.45% Upside
GPLB Green Planet Bioengineering	0.00	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	2.50	Moderate Buy	$7.00	204.35% Upside

Current Analyst Ratings Breakdown

Latest GPLB, SXTP, CERO, and ENVB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/23/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/23/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
6/11/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/2/2025	SXTP 60 Degrees Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.80 ➝ $7.00
5/30/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/30/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/24/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/19/2025	CERO CERo Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
5/10/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/24/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERO CERo Therapeutics	N/A	N/A	N/A	N/A	($41.98) per share	N/A
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	$2.35 per share	N/A
GPLB Green Planet Bioengineering	N/A	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	$300K	11.27	N/A	N/A	($6.38) per share	-0.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERO CERo Therapeutics	-$8.30M	N/A	0.00	∞	N/A	N/A	N/A	-199.71%	8/13/2025 (Estimated)
ENVB Enveric Biosciences	-$9.57M	-$38.38	N/A	N/A	N/A	N/A	-250.28%	-195.57%	8/11/2025 (Estimated)
GPLB Green Planet Bioengineering	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	-$7.95M	-$50.41	N/A	N/A	N/A	-1,947.30%	N/A	-174.90%	8/13/2025 (Estimated)

Latest GPLB, SXTP, CERO, and ENVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	N/A	CERO CERo Therapeutics	N/A	-$31.80	N/A	-$1.59	N/A	N/A
5/15/2025	Q1 2025	SXTP 60 Degrees Pharmaceuticals	-$1.31	-$1.56	-$0.25	-$1.56	$0.15 million	$0.18 million
5/14/2025	Q1 2025	ENVB Enveric Biosciences	-$3.45	-$1.22	+$2.23	-$1.22	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERO CERo Therapeutics	N/A	N/A	N/A	N/A	N/A
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	N/A
GPLB Green Planet Bioengineering	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERO CERo Therapeutics	N/A	0.73	0.73
ENVB Enveric Biosciences	N/A	4.08	4.08
GPLB Green Planet Bioengineering	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	3.14	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERO CERo Therapeutics	29.64%
ENVB Enveric Biosciences	13.82%
GPLB Green Planet Bioengineering	N/A
SXTP 60 Degrees Pharmaceuticals	7.96%

Insider Ownership

Company	Insider Ownership
CERO CERo Therapeutics	12.72%
ENVB Enveric Biosciences	3.20%
GPLB Green Planet Bioengineering	N/A
SXTP 60 Degrees Pharmaceuticals	10.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERO CERo Therapeutics	8	390,000	337,000	N/A
ENVB Enveric Biosciences	20	2.47 million	2.39 million	Not Optionable
GPLB Green Planet Bioengineering	1	20.01 million	N/A	Not Optionable
SXTP 60 Degrees Pharmaceuticals	3	1.47 million	1.32 million	Not Optionable

GPLB, SXTP, CERO, and ENVB Headlines

Recent News About These Companies

Weiss Ratings Reiterates Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

June 28 at 2:28 AM | americanbankingnews.com

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Director Cheryl Xu Acquires 5,000 Shares

June 6, 2025 | insidertrades.com

60 Degrees Pharmaceuticals Reports Significant Discrepancy in Babesiosis Case Estimates and Plans for New Drug Application in 2026

June 5, 2025 | nasdaq.com

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

June 4, 2025 | globenewswire.com

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

June 3, 2025 | globenewswire.com

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

May 15, 2025 | globenewswire.com

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

April 22, 2025 | globenewswire.com

Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?

April 10, 2025 | insidermonkey.com

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

April 10, 2025 | globenewswire.com

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

April 10, 2025 | globenewswire.com

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

April 8, 2025 | globenewswire.com

60 Degrees Pharmaceuticals, Inc.

April 4, 2025 | uk.investing.com

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

February 21, 2025 | accessnewswire.comA

60 Degrees Pharmaceuticals announces 1-for-5 reverse stock split

February 20, 2025 | markets.businessinsider.com

60 Degrees Pharmaceuticals, Inc. Announces 1-for-5 Reverse Stock Split to Comply with Nasdaq Listing Requirements

February 20, 2025 | quiverquant.comQ

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

February 20, 2025 | globenewswire.com

60 Degrees says FDA does not object to tafenoquine import plan

February 11, 2025 | markets.businessinsider.com

60 Degrees Pharmaceuticals, Inc. Receives FDA Approval for Importing KODATEF® as Preemptive Measure for ARAKODA® Supply Stability

February 11, 2025 | quiverquant.comQ

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

February 11, 2025 | globenewswire.com

Insiders Give Up US$71k As 60 Degrees Pharmaceuticals Stock Drops To US$0.55

February 9, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPLB, SXTP, CERO, and ENVB Company Descriptions

CERo Therapeutics NASDAQ:CERO

$9.55 -1.13 (-10.58%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$10.01 +0.46 (+4.82%)

As of 06/27/2025 07:57 PM Eastern

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Enveric Biosciences NASDAQ:ENVB

$1.24 -0.03 (-2.36%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.24 0.00 (0.00%)

As of 06/27/2025 07:38 PM Eastern

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Green Planet Bioengineering OTCMKTS:GPLB

$0.04 0.00 (0.00%)

As of 06/27/2025

Green Planet Bioengineering Co. Ltd. operates as a shell company, with the purpose of acquisition and merging with an existing business operation. The company was founded on October 30, 2006 and is headquartered in Aventura, FL.

60 Degrees Pharmaceuticals NASDAQ:SXTP

$2.30 -0.14 (-5.74%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.16 -0.14 (-5.87%)

As of 06/27/2025 06:50 PM Eastern

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time